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Abstract
Background: The currently available data with respect to the association between vitamin D receptor (VDR) gene
polymorphism and risk to urolithiasis are inconclusive and inconsistent. Hence, an exhaustive meta-analysis can
solve the discrepancies and provide a hint for upcoming investigations. Herein, a meta-analysis was carried out to
attain a conclusive estimate of the association between VDR gene single nucleotide polymorphisms (SNPs) and
urolithiasis risk.
Methods: The major databases, including ISI Web of science, Scopus, and PubMed/MEDLINE were searched
systematically from until June 2020 to retrieve all relevant studies. Association between VDR gene polymorphisms,
including FokI (rs2228570), TaqI (rs731236), BsmI (rs1544410), and ApaI (rs7975232), and urolithiasis risk was
evaluated using pooled odds ratio (OR) and their corresponding 95% confidence interval (CI). Additionally, to seek
for the potential source of heterogeneity, meta-regression analyses were exerted.
Results: Literature search led to finally finding of 33 studies evaluating the VDR gene SNPs and urolithiasis risk. It
was observed that none of the four SNPs were significantly associated with urolithiasis predisposition. However,
subgroup analysis confirmed higher risk of urolithiasis in East-Asian and Caucasian population with ApaI and TaqI
gene polymorphism. The analyses of sensitivity acknowledged the results stability.
Conclusion: Although this meta-analysis did not support the association of FokI, TaqI, BsmI, and ApaI in the overall
polled analysis, it suggests that ApaI and TaqI SNPs is associated with increased risk of urolithiasis in East-Asian and
Caucasians populations.
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Background
Urolithiasis is known as one of the prevalent diseases
among urological disorders that has been associated with
many complicated factors [1]. Urolithiasis is character-
ized by a high recurrence incidence, and its prevalence
rate is 4–20% in developed countries, and the disease
incidence continues to increase [2]. It is a multifactorial
disorder, resulting from environmental influences, meta-
bolic defects and genetic factors [3]. Numerous investi-
gations recognized the importance of genes in this
disorder.
Studies have shown that several genetic factors includ-
ing single nucleotide polymorphisms (SNPs) in osteo-
pontin (OPN), progestin and adiporeceptor 6 (PAQR6),
calcium-sensing receptor (CaSR), and vitamin D recep-
tor (VDR) are correlated with the risk of urinary calcium
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stone formation [4–7]. In spite of attribution of a genetic
background in susceptibility to urolithiasis, little has
been identified with respect to the relevant genetic loci
for the disease. Two genome-wide association studies
(GWASs) recognized four risk susceptibility genes, in-
cluding CLDN14 in Europeans and Japanese [8, 9],
INMT-FAM188B-AQP1, RGS14-SLC34A1-PFN3-F12,
and DGKH in Japanese [9]. That notwithstanding, these
studies suggested further studies was needed to identify
more risk loci as well as to recognize the molecular
mechanisms attributed to the urinary calculi.
Broadly speaking, complex interactions of genetics and
environmental factors, such as water intake, diet, urine
pH, and infections have been associated with the etio-
pathogenesis of urolithiasis [10]. The underlying mecha-
nisms of the development of calcium-containing stones,
which are the most common type of kidney and bladder
stones, have not fully been divulged [11]. Nowadays, the
possibility of both free and fixed stones development has
been suggested. The widely accepted explanation of the
development of such stones relies on the increased solu-
bility of the lithogenic elements in the urine [11].
Furthermore, it has been contemplated that the depos-
ition of initial crystals occurs in the lumens of renal tu-
bules [12, 13]. However, recent observations imply that a
development of Randall plaques in the renal papilla is
the initial trigger of stone formation [14]. Such plaques
are developed when calcium phosphate crystals are de-
posited in the basement of the thin loops of Henle and
then extend into the urothelium. Calcium oxalate stones,
which are responsible for almost 80% of all urinary
stones, are developed after formation of calcium phos-
phate crystals. In fact, the binding of more calcium oxal-
ate as well as matrix molecules present in the urine to
the Randall plaques accelerates the formation of calcium
oxalate stones [15].
Recent studies have demonstrated that receiving
vitamin D supplements maybe put the individual at
risk of developing kidney stones disease [16]. More-
over, vitamin D has an important role in calcium me-
tabolism, such as absorption of calcium from intestine
and its reabsorption in the kidneys. it through in-
creasing the serum calcium levels could enhance the
risk of urinary stone formation [17]. Vitamin D func-
tions are dependent on the expression and nuclear
activation of VDR [18]. Therefore, any alteration in
the VDR may change the calcium metabolism, thus
alter the urolithiasis risk. Taken together, studies have
recommended that VDR play an essential role in the
pathogenesis of urolithiasis [19].
The human VDR gene is placed on the chromosome
12q12–q14 that harbors more than 200 SNPs, among
which FokI (or rs2228570), TaqI (or rs731236), BsmI (or
rs1544410), and ApaI (or rs7975232) polymorphisms
have been extensively investigated. VDR gene has at least
five promoter regions, six untranslated exons, and eight
protein-coding exons, which are alternatively spliced
into BsmI, FokI, ApaI, and TaqI [20].. BsmI and ApaI
are placed on the 9th intron of the 3′ terminal, TaqI is
located on the 9th exon of the 3′ terminal, and FokI is
established on the promoter of the 5′ terminal. Studies
have reported that BsmI and TaqI SNPs are not involved
in altering the protein structure of VDR; however, they
have been suggested to play a role in the translation
efficiency and stability of the corresponding mRNA [21].
Numerous studies have indicated the association of poly-
morphisms in the VDR gene with several human
diseases [22, 23].
A series of studies investigated the association between
these polymorphisms of VDR gene and the risk of uro-
lithiasis, but the findings have been conflicting [24–50].
The inconsistent results were possibly because of clinical
heterogeneity, small sample sizes, and low statistical
power. In addition, previous meta-analyses [51–53] ap-
peared to be out of date due to the availability of new
data [45–50]. Therefore, we performed the most up to
date meta-analysis with the aim of obtaining more ac-
curate and updated results.
Methods
This study was performed in a stepwise process in ac-
cordance with the guidelines of the 2009 Preferred
Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) statement [54]. Besides, the current
project does not contain any studies with human partici-
pants or animals performed by any of the authors. Regis-
tration in the International Prospective Register of
Systematic Reviews (PROSPERO) was carried out.
Literature identification
A detailed systematic search was performed to identify
candidate studies evaluating the associations between
VDR gene polymorphisms and urolithiasis susceptibility
(prior to June 2020). Three electronic databases, includ-
ing Web of Science, MEDLINE, and Scopus were
searched and for all of them, following combination of
key words were used: (“urolithiasis” or “Kidney stone
disease”) AND (“VDR” OR “vitamin D receptor”) AND
(“polymorphisms” OR “SNP” OR “variation” OR “muta-
tion”). Cross references within both original and review
publications were done for additional pertinent studies.
Original data were collected from English language and
human population studies.
Inclusion/exclusion criteria
Studies included in quantitative analysis if met the fol-
lowing inclusion criteria: a) studies concerning the asso-
ciation between VDR gene polymorphisms and
Imani et al. BMC Nephrology          (2020) 21:263 Page 2 of 18
urolithiasis risk; b) Studies with case-control design; c)
studies reporting sufficient data of genotype or allele fre-
quency in order to calculate odds ratios (ORs) and 95%
confidence intervals (CIs). On the other hand, duplicate
data, case report, book chapter, review, letter, and ab-
stracts were excluded.
Data extraction
All required data were extracted conforming to the stan-
dardized extraction checklist for the following data: the
first author’s name, journal and year of publication,
country of origin, ethnicity, number of subjects in the
case and control groups, mean or range of age, genotyp-
ing method, genotype counts in the case and control
group. The extracted items were compared and any pos-
sible discrepancies were resolved by consensus.
Quality assessment
Methodological quality of eligible studies was evaluated
by Newcastle–Ottawa Scale (NOS), a validated scale for
non-randomized studies in meta-analysis. This scale
consists of 3 parts with a total of 9 items. In this regards,
studies with scores 0–3, 4–6 or 7–9 were of low, moder-
ate, or high-quality, respectively [55].
Statistical analysis
For evaluating the distribution of the genotype frequen-
cies to see if it is deviated from Hardy–Weinberg equi-
librium (HWE) in the control group, the χ2-test was
employed [56]. The quality of association between VDR
gene SNPs and urolithiasis risk was evaluated by the
pooled OR and its corresponding 95% CI. Five different
comparison model for FokI, TaqI, BsmI, and ApaI SNPs
were as follow: dominant model, recessive model, allelic
model, homozygote contrast, and heterozygote contrast.
Presence of heterogeneity between included studies was
estimated by Cochran’s Q-statistic (P value< 0.10 was
considered as statistically significant). Besides, to report
quantitative heterogeneity, the I-squared (I2) test was
used. The fixed-effected model was used if PQ statistic>
0.10 or I2 was< 50%; otherwise, the random-effected
model was applied [57, 58]. We assessed the predefined
sources of heterogeneity among included studies by sub-
group analysis and meta-regression analysis based on
year of population, and genotyping method. The stability
of our results was measured by sensitivity analysis. Add-
itionally, sensitivity analysis was conducted in the pres-
ence of heterogeneity. Moreover, Begg’s test, Egger’s
regression test and visual examination of the funnel plot
were applied to measure publication bias (P value< 0.05
was considered as statistically significant) [59]. The data
analyses were carried out using STATA (version 14.0;
Stata Corporation, College Station, TX) and SPSS
(version 23.0; SPSS, Inc. Chicago, IL).
Results
Specifications of the included studies
The exact process of literature searches and study selec-
tion is depicted in the Fig. 1. Early literature search
eventuated in identification of 207 records, 33 of which
met the final inclusion criteria and included in quantita-
tive analysis. Among 33 eligible studies, 20 studies inves-
tigated the FokI SNP, 22 studies TaqI SNP, 14 studies
BsmI SNP and 16 studies ApaI SNP. The studies were
published between 1999 and 2020 and had an overall
good methodological quality with NOS scores ranging
from 5 to 8. Polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP) and Taq-Man
were used by majority of included studies as genotyping
method. Tables 1 and 2 summarized the characteristics
of the included studies.
Quantitative synthesis
As the reference categories for comparing, the FF geno-
type for FokI SNP, TT genotype for TaqI SNP, BB geno-
type for BsmI SNP, and AA genotype for ApaI were
used.
Association of FokI polymorphism and urolithiasis risk
Twenty studies, including 3114 urolithiasis patients and
3174 controls, evaluated the FokI polymorphism. Of
which, 14 studies were conducted in Asian countries
[26, 28, 34, 35, 37, 40–42, 44, 50, 60–63] and 6 studies
were in European countries [31–33, 48, 64, 65]. Overall,
no significant association was detected between FokI
SNP and urolithiasis risk under all five genetic models.
Besides, the findings of subgroup analysis reject any as-
sociation between FokI SNP and risk of urolithiasis in
East-Asians and Caucasians.
Association of TaqI polymorphism and urolithiasis risk
Twenty-two case-control studies with 4188 cases and
3955 controls met inclusion criteria for evaluating the
association between TaqI SNP and urolithiasis risk.
Among them, ten studies were performed in Asian
population [28, 40–42, 44, 60–63, 66] and eleven studies
were in European population [29, 31, 36, 38, 39, 45, 46,
48, 65, 67] and one study in the USA [24]. The pooled
results did not indicate significant association between
TaqI SNP and urolithiasis risk except in tt vs. TT model
(OR = 1.27, 95% CI = 1.01–1.59, P = 0.04), also subgroup
analysis revealed that the tt genotype was associated with
urolithiasis risk in Caucasians when compared with the
TT genotype [tt vs. TT (OR = 1.30, 95% CI = 1.021–1.65,
P = 0.03)], Fig. 2.
Association of BsmI polymorphism and urolithiasis risk
Fourteen eligible publications with 3065 cases and 2915
controls were included and evaluated the association
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between BsmI polymorphism and urolithiasis risk.
Among 14 studies, only five publications were carried
out in Asia [27, 44, 62, 66, 68] and nine studies were in
Europe [25, 29, 31–33, 36, 38, 46, 48, 65]. The statistical
analysis demonstrated that there was no significant asso-
ciation between BsmI SNP and urolithiasis risk under
any genetic models in both the overall population and
the subgroup analysis.
Association of ApaI polymorphism and urolithiasis risk
A total of 16 publications containing 2950 cases and
3065 controls were recognized eligible for evaluating the
association between ApaI SNP and urolithiasis risk. Of
which, eight studies were performed in Asians [27, 28,
40, 44, 61, 66, 68] and eight studies were in Europeans
[29, 33, 36, 38, 41, 45, 46, 48, 64]. The pooled results re-
vealed a marginal significant association between ApaI
SNP and urolithiasis risk under recessive model (OR =
1.14, 95% CI = 1.01–1.29, p = 0.03), allelic model (OR =
1.09, 95% CI = 1–1.18, P = 0.05), and aa vs. AA model
(OR = 1.21, 95% CI = 1–1.47, P = 0.05). Additionally, the
results of subgroup analysis indicated a positive signifi-
cant association in East-Asians across recessive model
(OR = 1.20, 95% CI = 1.05–1.37, P < 0.001), allelic model
(OR = 1.15, 95% CI = 1.05–1.26, P < 0.001), and aa vs.
AA model (OR = 1.40, 95% CI = 1.12–1.75, P < 0.001) but
not Caucasians. The results of pooled ORs, heterogen-
eity tests, and publication bias tests for different analysis
models are shown in Table 3.
Evaluation of the heterogeneity and publication bias
The results of publication bias test indicated that there
was no evidence of publication bias for overall popula-
tion and subgroup analysis of all FokI, TaqI, BsmI, and
ApaI SNPs. Additionally, the shape of the funnel plot
confirmed absence of publication bias. No heterogeneity
in both the overall and subgroup analyses was detected
except for FokI polymorphism (Fig. 3, Table 3).
Sensitivity analysis
Sensitivity analysis is an effective test to evaluate the in-
fluence of individual study on the pooled results. In the
sensitivity analysis, each eligible study was sequentially
removed to assess whether the individual data influence
the pooled ORs. In this meta-analysis, the pooled results
did not significantly affect by any single study in the
dominant model for FokI, TaqI, BsmI and ApaI SNPs
Fig. 1 Flow diagram of study selection process
Imani et al. BMC Nephrology          (2020) 21:263 Page 4 of 18
Table 1 Characteristics of studies included in meta-analysis of overall Urolithiasis







Chen et al. (b) 2001 China Asian M = 101/42
F = 45/48
146 / 90 44.2 / 55.5 PCR–RFLP 6
Shaogang et al. 2003 China Asian M = 89/ 58
F = 61/22
150 / 80 43.6 ± 16/ 49 ± 19.6 PCR–RFLP 6
Rendina et al. 2004 Italy European M = 94/72
F = 65/52
159 / 124 43 ± 10.8 / 41.9 ± 10.4 PCR–RFLP 7
Mossetti et al. 2004 Italy European M = 66/ 73
F = 44/54
110 / 127 41.3 ± 13.5 / 41.06 ± 13.9 PCR–RFLP 6
Relan et al. 2004 India Asian M = 105/76
F = 45/24
150 / 100 39.3 ± 1.1 / 43.2 ± 2.05 PCR–RFLP 7
Bid et al. (a) 2005 India Asian M = NR
F=NR
113 / 132 21–72 / 22–58 PCR–RFLP 6
Bid et al. (b) 2005 India Asian M = NR
F=NR
50 / 60 2–14 / 4–16 PCR–RFLP 5
Liu et al. 2007 China Asian M = 161/159
F = 74/72
235 / 231 50.1 ± 12.3 / 51.7 ± 11.1 PCR–RFLP 8
Seo et al. 2009 Korea Asian M = 93/ 220
F = 185/313
278 / 533 49.9 / 40.1 PCR–RFLP 8
Mittal et al. 2010 India Asian M = NR
F=NR
125 / 150 40 ± 11.5 / 41.5 ± 10.5 PCR–RFLP 7
Basiri et al. 2012 Iran Asian M = NR
F=NR
102 / 106 43.4 ± 6.9 / 38.4 ± 6.9 SSP-PCR 6
Kaysar et al. 2012 China Asian M = NR
F=NR
74 / 103 NR PCR–RFLP 5
Wang et al. 2012 China Asian M = 279/263
F = 185/187
464 / 450 50.01 ± 10.19 / 50.45 ± 11.22 PCR–RFLP 8
Guha et al. 2015 India Asian M = 133 / 112
F = 67 / 78
200 /200 39.93 ± 11 / 38.13 ± 10 PCR 7
Cakir et al. 2016 Turkey European M = 65 / 52
F = 33 / 18
98 / 70 47.2 ± 16.3 / 42.6 ± 13.5 PCR–RFLP 6
Ergon et al. 2017 Turkey European M = NR
F=NR
27 / 13 7.12 ± 2.64 / 6.92 ± 2.48 Tag-man 5
Subasi et al. 2017 Turkey European M = 26/22
F = 26/29
52 / 51 9.8 ± 3.5 / 10.3 ± 3.7 SNaPshot 5
Li et al. 2018 China Asian M = 100/60
F = 100/60
200 / 120 35.88 ± 14.2 / 36.16 ± 15.20 PCR 7
Huang et al. 2019 China Asian M = NR
F=NR
130 / 224 4.55 ± 3.19 / 5.02 ± 3.50 PCR–RFLP 7
Amar et al. 2019 Pakistani Asian M = NR
F=NR
235 / 243 NR PCR–RFLP 7
TaqI (rs731236)
Jackman et al. 1999 USA American M = NR
F=NR
17 / 37 NR PCR–RFLP 5
Nishijima et al. 2002 Japan Asian M = NR
F=NR
83 / 83 51.8 ± 15.6 / 54.4 ± 13.1 PCR–RFLP 5
Ozkaya et al. 2003 Turkey European M = 26/ 47
F = 38/43
64 / 90 6.7 ± 3.5 / 7.2 ± 2.3 PCR–RFLP 5
Mossetti et al. 2003 Italy European M = NR
F=NR
220/114 40.87 ± 14.95 / 40.37 ± 14.07 PCR–RFLP 7
Shaogang et al. 2003 China Asian M = 89/ 58
F = 61/22
150 / 80 43.6 ± 16 / 49 ± 19.6 PCR–RFLP 6
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Table 1 Characteristics of studies included in meta-analysis of overall Urolithiasis (Continued)






Mossetti et al. 2004 Italy European M = 66/ 73
F = 44/54
110 / 127 41.3 ± 13.5 / 41.06 ± 13.9 PCR–RFLP 6
Gunes et al. 2006 Turkey European M = 67/ 73
F = 43/77
110 / 150 49.22 ± 1.33 / 48.15 ± 1.62 PCR–RFLP 7
Sayan et al. 2007 Turkey European M = 65/ 25
F = 15/15
80 / 40 10.9 ± 0.6 / 10.5 ± 0.6 PCR–RFLP 5
Moyano et al. 2007 Spain European M = 22/ 9
F = 29/12
51 / 21 45.5 ± 13.5 / 48.6 ± 15.4 PCR–RFLP 5
Seo et al. 2009 Korea Asian M = 93/ 220
F = 185/313
278 / 533 49.9 / 40.1 PCR–RFLP 8
Mittal et al. 2010 India Asian M = NR
F=NR
125 / 150 40 ± 11.5 / 41.5 ± 10.5 PCR–RFLP 7
Basiri et al. 2012 Iran Asian M = NR
F=NR
102 / 106 43.4 ± 6.9 / 38.4 ± 6.9 SSP-PCR 6
Wang et al. 2012 China Asian M = 279/263
F = 185/187
464 / 450 50.01 ± 10.19 / 50.45 ± 11.22 PCR–RFLP 8
Aykan et al. 2015 Turkey European M = 100/87
F = 64/ 80
164 / 167 24–58 / 38–54 PCR–RFLP 7
Guha et al. 2015 India Asian M = 133 / 112
F = 67 / 78
200 / 200 39.93 ± 11 / 38.13 ± 10 PCR 7
Rendina et al. 2016 Italy European M = NR
F=NR
372 / 88 41.2 ± 13.3 / 40.8 ± 14.1 PCR–RFLP 7
Cakir et al. 2016 Turkey European M = 65 / 52
F = 33 / 18
98 / 70 47.2 ± 16.3 / 42.6 ± 13.5 PCR–RFLP 6
Goknar et al. 2016 Turkey European M = NR
F=NR
78 / 60 6.94 ± 3.8 / 7.5 ± 3.2 PCR–RFLP 6
Subasi et al. 2017 Turkey European M = 26/22
F = 26/29
52 / 51 9.8 ± 3.5 / 10.3 ± 3.7 SNaPshot 5
Li et al. 2018 China Asian M = 100/60
F = 100/60
200 / 120 35.88 ± 14.2 / 36.16 ± 15.20 PCR 7
Yang et al. 2019 China Asian M = 627/614
F = 316/361
943 / 975 51.2 ± 14.13 / 54.33 ± 18.11 iMLDR 8
Amar et al. 2019 Pakistani Asian M = NR
F=NR
227 / 243 NR PCR–RFLP 7
BsmI (rs1544410)
Ruggiero et al. 1999 Italy European M = 18/NR
F = 9/ NR
27 / 150 NR PCR–RFLP 6
Chen et al. (a) 2001 China Asian M = 94/55
F = 30/ 35
124 / 90 44.1 ± 11.5 / 53 ± 10.1 PCR–RFLP 6
Ozkaya et al. 2003 turkey European M = 26/ 47
F = 38/43
64 / 90 6.7 ± 3.5 / 7.2 ± 2.3 PCR–RFLP 5
Rendina et al. 2004 Italy European M = 94/72
F = 65/52
159 / 124 43 ± 10.8 / 41.9 ± 10.4 PCR–RFLP 7
Mossetti et al. 2004 Italy European M = 66/ 73
F = 44/54
110 / 127 41.3 ± 13.5 / 41.06 ± 13.9 PCR–RFLP 6
Relan et al. 2004 India Asia M = 105/76
F = 45/24
150 / 100 39.3 ± 1.1 / 43.2 ± 2.05 PCR–RFLP 7
Gunes et al. 2006 turkey European M = 67/ 73
F = 43/77
110 / 150 49.22 ± 1.33 / 48.15 ± 1.62 PCR–RFLP 7
Moyano et al. 2007 Spain European M = 22/ 9
F = 29/12
51 / 21 45.5 ± 13.5 / 48.6 ± 15.4 PCR–RFLP 5
Wang et al. 2012 China Asian M = 279/263
F = 185/187
464 / 450 50.01 ± 10.19 / 50.45 ± 11.22 PCR–RFLP 8
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(Fig. 4), indicating that the combined results of our
meta-analysis were statistically robust.
Meta-regression analyses
Potential sources of heterogeneity among included stud-
ies was estimated by meta-regression analyses (Table 4).
According that, the findings indicated that none of the
expected heterogeneity parameter were the source of
heterogeneity for the association between VDR gene
polymorphism and the risk of urolithiasis (Fig. 5).
Discussion
In the current most recent meta-analysis, 33 case-
control association studies evaluating the VDR gene
SNPs and urolithiasis risk were analyzed. The results of
pooled analysis revealed that none of the four SNPs in
Table 1 Characteristics of studies included in meta-analysis of overall Urolithiasis (Continued)






Cakir et al. 2016 Turkey European M = 65 / 52
F = 33 / 18
98/ 70 47.2 ± 16.3 / 42.6 ± 13.5 PCR–RFLP 6
Goknar et al. 2016 Turkey European M = NR
F=NR
72/ 53 6.94 ± 3.8 / 7.5 ± 3.2 PCR–RFLP 6
Subasi et al. 2017 turkey European M = 26/22
F = 26/29
52 / 51 9.8 ± 3.5 / 10.3 ± 3.7 SNaPshot 5
Li et al. 2018 China Asian M = 100/60
F = 100/60
200 / 120 35.88 ± 14.2 / 36.16 ± 15.20 PCR 7
Yang et al. 2019 China Asian M = 627/614
F = 316/361
943 / 975 51.2 ± 14.13 / 54.33 ± 18.11 iMLDR 8
ApaI (rs7975232)
Nishijima et al. 2002 Japan Asian M = NR
F=NR
83 / 83 51.8 ± 15.6 / 54.4 ± 13.1 PCR–RFLP 5
Shaogang et al. 2003 China Asian M = 89/ 58
F = 61/22
150 / 80 43.6 ± 16 / 49 ± 19.6 PCR–RFLP 6
Ozkaya et al. 2003 Turkey Asian M = 26/ 47
F = 38/43
64 / 90 6.7 ± 3.5 / 7.2 ± 2.3 PCR–RFLP 5
Rendina et al. 2004 Italy European M = 94/72
F = 65/52
159 / 124 43 ± 10.8 / 41.9 ± 10.4 PCR–RFLP 7
Gunes et al. 2006 Turkey European M = 67/ 73
F = 43/77
110 / 150 49.22 ± 1.33 / 48.15 ± 1.62 PCR–RFLP 7
Moyano et al. 2007 Spain European M = 22/ 9
F = 29/12
51 / 21 45.5 ± 13.5 / 48.6 ± 15.4 PCR–RFLP 5
Seo et al. 2009 Korea Asian M = 88/ 220
F = 185/305
273 / 525 49.9 / 40.1 PCR–RFLP 8
Mittal et al. 2010 India Asian M = NR
F=NR
125 / 150 40 ± 11.5 / 41.5 ± 10.5 PCR–RFLP 7
Kaysar et al. 2012 China Asian M = NR
F=NR
74 / 103 NR PCR–RFLP 5
Wang et al. 2012 China Asian M = NR
F=NR
463 / 450 50.01 ± 10.19 / 50.45 ± 11.22 PCR–RFLP 8
Cakir et al. 2016 Turkey European M = 65 / 52
F = 33 / 18
98/ 70 47.2 ± 16.3 / 42.6 ± 13.5 PCR–RFLP 6
Goknar et al. 2016 Turkey European M = NR
F=NR
78/ 60 6.94 ± 3.8 / 7.5 ± 3.2 PCR–RFLP 6
Ergon et al. 2017 Turkey European M = NR
F=NR
27 / 13 7.12 ± 2.64 / 6.92 ± 2.48 Tag-man 5
Subasi et al. 2017 Turkey European M = 26/22
F = 26/29
52 / 51 9.8 ± 3.5 / 10.3 ± 3.7 SNaPshot 5
Li et al. 2018 China Asian M = 100/60
F = 100/60
200 / 120 35.88 ± 14.2 / 36.16 ± 15.20 PCR 7
Yang et al. 2019 China Asian M = 627/614
F = 316/361
943 / 975 51.2 ± 14.13 / 54.33 ± 18.11 iMLDR 8
Abbreviations: NR not reported, M male, F female
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Table 2 Distribution of genotype and allele among urolithiasis patients and controls
Study author Urolithiasis cases Healthy control P-HWE MAF
FF Ff ff F F FF Ff ff F f
FokI (rs2228570)
Chen et al. (b) 54 67 25 175 117 21 43 26 85 95 0/43 0/527
Shaogang et al. 27 64 59 118 182 17 44 19 78 82 0/36 0/512
Rendina et al. 69 68 22 206 112 53 55 16 161 87 0/77 0/350
Mossetti et al. 43 47 20 133 87 53 55 19 161 93 0/45 0/366
Relan et al. 25 72 53 122 178 38 36 26 112 88 0/01 0/44
Bid et al. (a) 30 106 2 136 90 77 84 5 238 94 0/02 0/257
Bid et al. (b) 11 38 1 60 40 30 28 2 88 32 0/13 0/266
Liu et al. 64 113 58 241 229 58 116 57 232 230 0/94 0/497
Seo et al. 84 134 60 302 254 155 288 92 598 472 0/03 0/441
Mittal et al. 25 98 2 214 86 69 76 5 148 102 < 0.01 0/408
Basiri et al. 54 42 6 150 54 36 27 43 99 113 < 0.01 0/533
Kaysar et al. 19 43 12 81 67 33 39 31 105 101 0/01 0/490
Wang et al. 150 234 80 534 394 125 226 99 476 424 0/86 0/471
Guha et al. 78 115 7 271 129 98 90 12 286 114 0/74 0/542
Cakir et al. 48 38 12 134 62 39 25 6 103 37 0/39 0/618
Ergon et al. 14 12 1 40 14 7 6 0 20 6 0/27 0/230
Subasi et al. 23 25 4 71 33 26 21 4 73 29 0/93 0/284
Li et al. 38 102 60 178 222 31 72 17 134 106 0/02 0/4416
Huang et al. 73 49 8 195 65 104 96 24 304 144 0/79 0/321
Amar et al. 136 79 11 351 101 146 77 10 369 97 0.37 0.519
Study author Urolithiasis cases Healthy control P-HWE MAF
TT Tt tt T t TT Tt tt T t
TaqI (rs731236)
Jackman et al. 6 7 4 19 15 17 8 12 42 32 0/82 0/432
Nishijima et al. 49 30 4 128 38 60 22 1 142 24 0/1 0/228
Ozkaya et al. 33 27 4 93 35 50 30 10 130 50 0/81 0/277
Mossetti et al. 80 104 36 264 176 35 66 13 136 92 0/53 0/719
Shaogang et al. 52 74 24 178 122 33 36 11 102 58 0/3 0/362
Mossetti et al. 21 53 36 95 125 21 68 38 110 144 0/39 0/566
Gunes et al. 37 63 10 137 83 61 73 16 195 105 0/02 0/35
Shayan et al. 27 35 18 89 71 13 25 2 51 29 0/74 0/362
Moyano et al. 15 23 13 53 49 9 10 2 28 14 < 0.01 0/333
Seo et al. 252 23 3 527 29 487 39 7 1013 53 0/05 0/049
Mittal et al. 56 61 8 173 77 84 50 16 218 82 0/03 0/273
Basiri et al. 41 50 11 132 72 52 37 17 141 71 0/77 0/334
Wang et al. 430 32 2 892 36 414 35 1 863 37 0/08 0/041
Aykan et al. 67 61 36 195 133 66 86 15 218 116 < 0.01 0/347
Guha et al. 58 82 60 196 202 65 58 77 188 212 0/67 0/349
Rendina et al. 186 158 28 530 214 31 44 13 106 70 0/16 0/473
Cakir et al. 35 44 19 114 82 31 29 10 91 49 0/43 0/173
Goknar et al. 25 41 12 91 65 14 43 3 71 49 0/83 0/408
Subasi et al. 4 25 23 33 71 9 24 18 42 60 0/77 0/588
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VDR gene were in significant association with proneness
to urolithiasis. That notwithstanding, subgroup analysis
based on the population stratification demonstrated
increased risk of urolithiasis in East-Asian (recessive, al-
lelic and aa vs. AA model) and Caucasian (heterozygous
model) population with ApaI and TaqI gene polymorph-
ism, respectively.
Several investigations have noted that VDR gene SNPs
have been contributing genetic factors in susceptibility
to urolithiasis [27, 31, 34, 49]. A bulk of studies have
Table 2 Distribution of genotype and allele among urolithiasis patients and controls (Continued)
Li et al. 189 11 0 389 11 114 6 0 234 6 0/82 0/025
Yang et al. 849 92 2 1790 96 870 103 2 1843 107 0/67 0/471
Amar et al. 112 86 29 310 144 116 104 23 336 150 0/42 0/149
Study author Urolithiasis cases Healthy control P-HWE MAF
BB Bb bb B b BB Bb bb B b
BsmI (rs1544410)
Ruggiero et al. 4 12 11 19 35 18 108 24 144 156 < 0.01 0/52
Chen et al. (a) 110 10 4 230 18 78 9 3 165 15 < 0.01 0/083
Ozkaya et al. 5 36 23 46 82 13 49 28 75 105 0/25 0/583
Rendina et al. 47 69 43 163 155 39 56 29 134 114 0/31 0/459
Mossetti et al. 40 46 24 126 94 40 56 31 136 118 0/2 0/464
Relan et al. 48 62 40 158 142 46 28 26 120 80 < 0.01 0/40
Gunes et al. 15 64 31 94 126 19 75 56 113 187 0/42 0/623
Moyano et al. 5 25 21 35 67 5 9 7 19 23 0/53 0/547
Wang et al. 3 66 395 72 856 2 70 378 74 826 0/51 0/917
Cakir et al. 43 40 15 126 70 26 34 10 86 54 0/57 0/476
Goknar et al. 21 35 16 77 67 16 37 0 69 37 0/01 0/349
Subasi et al. 28 19 5 75 29 20 23 8 63 39 0/74 0/382
Li et al. 181 19 0 381 19 111 9 0 231 9 0/67 0/0375
Yang et al. 65 394 484 524 1362 78 417 480 573 1377 0/28 0/315
Study author Urolithiasis cases Healthy control P-HWE MAF
AA Aa aa A a AA Aa aa A a
ApaI (rs7975232)
Nishijima et al. 14 34 35 62 104 9 37 37 55 111 0/25 0/626
Shaogang et al. 32 69 49 133 167 11 38 31 60 100 0/9 0/625
Ozkaya et al. 13 30 21 56 72 4 50 36 58 122 0/09 0/677
Rendina et al. 43 87 29 173 145 37 68 19 142 106 0/18 0/427
Gunes et al. 40 58 12 138 82 59 72 19 190 110 0/68 0/366
Moyano et al. 11 29 11 51 51 7 9 5 23 19 0/53 0/452
Seo et al. 152 84 37 388 158 282 192 51 756 294 0/03 0/28
Mittal et al. 43 70 12 156 94 57 71 22 185 115 0/98 0/383
Kaysar et al.. 21 29 24 71 77 32 42 29 106 100 0/06 0/485
Wang et al 27 177 259 231 695 46 195 209 287 613 0/75 0/748
Cakir et al. 43 40 15 126 70 26 34 10 86 54 0/63 0/135
Goknar et al. 24 42 12 90 66 11 40 9 62 58 0/01 0/483
Ergon et al. 9 12 6 30 24 4 6 3 14 12 0/79 0/461
Subasi et al. 18 24 10 60 44 22 14 15 58 44 0/01 0/431
Li et al. 73 87 40 233 167 57 51 12 165 75 0/9 0/312
Yang et al. 65 394 484 524 1362 78 417 480 573 1377 0/49 0/743
Abbreviations: P-HWE p-value for Hardy–Weinberg equilibrium, MAF minor allele frequency of control group
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attempted to disclose the possible association between
VDR gene SNPs and urolithiasis risk; that notwithstand-
ing, the findings still show discrepancies and a compre-
hensive meta-analysis seems to be required to shed
insights on the unknown conundrums. As a result, we
performed a meta-analysis to investigate the conse-
quence of the common four SNPs in the VDR gene,
namely FokI (rs2228570), TaqI (rs731236), BsmI
(rs1544410), and ApaI (rs7975232) on the risk of urolith-
iasis. The discrepancies in outcome among the various
ethnicities might be due to differences in geographic and
ethnical diversity, and impression of ethnicity on the
serum level of vitamin D as well as the VDR gene ex-
pression [69].
Reports have shown the role of environmental factors
on the risk of different diseases. For example, seasonal
differences may impress the serum level of vitamin D
[70]. Among the pregnant women in south-eastern USA,
season was indicated to be associated with vitamin D
levels in non-Hispanic women [71]. Sun exposure has
been shown to interact with functional variants of the
VDR gene [72]. Additionally, sun exposure and the
differences between high and low latitudes, it has been
implied that people in high latitude regions experience
lower levels of vitamin D, especially in those with darker
skin (which is a natural barrier to the UV radiation)
[73]. As a result, environmental stimuli may impress the
functional variants of the VDR gene as well as serum
levels of vitamin D and, hence, modify the risk of
urolithiasis susceptibility, along with VDR genetic
polymorphisms.
Vitamin D is a critical hormone and play a role in the
metabolism of calcium. This vitamin implements its
function by binding to the VDR. The genetic variations
in the VDR gene have been shown to impress the inter-
actions of the vitamin D/VDR, modulating the suscepti-
bility risk for several pathologic conditions. FokI
polymorphism can modulate the ATG start cordon in
Fig. 2 Pooled odds ratio (OR) and 95% confidence interval of individual studies and pooled data for the association between TaqI and ApaI gene
polymorphism and urolithiasis risk in different ethnicity subgroups and overall populations. a; tt vs. TT Model (TaqI) and b: A; Recessive
Model (ApaI)
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Table 3 Main results of pooled ORs in meta-analysis of VDR gene polymorphisms
Subgroup Sample size Test of association Test of
heterogeneity
Test of publication bias
(Begg’s test)
Test of publication bias
(Egger’s test)
Genetic model Case/Control OR 95%CI (p-value) I2 (%) P Z P T P
FokI (rs2228570)
Overall Dominant model 3114 / 3174 1.16 0.90–1.50(0.25) 77.7 ≤0.001 1.73 0.08 1.37 0.19
Recessive model 3114 / 3174 0.92 0.68–1.25(0.58) 67.2 ≤0.001 −1.17 0.24 −0.68 0.50
Allelic model 3114 / 3174 1.02 0.86–1.22(0.82) 78.5 ≤0.001 0.25 0.80 0.45 0.66
ff vs. FF 3114 / 3174 1.10 0.72–1.69(0.65) 77.9 ≤0.001 −0.72 0.47 −0.14 0.88
Ff vs. FF 3114 / 3174 1.12 0.88–1.43(0.34) 74.1 ≤0.001 1.94 0.05 1.39 0.18
East-Asian Dominant model 1677 / 1833 0.91 0.77–1.06(0.22) 1 0.42 0.99 0.32 1.64 0.15
Recessive model 1677 / 1833 0.98 0.66–1.45(0.91) 74.9 ≤0.001 0 1 −0.18 0.86
Allelic model 1677 / 1833 0.95 0.78–1.16(0.62) 71.6 ≤0.001 −0.25 0.80 0.15 0.88
ff vs. FF 1677 / 1833 0.93 0.61–1.40(0.71) 67.7 ≤0.001 0 1 0.10 0.92
Ff vs. FF 1677 / 1833 0.88 0.74–1.04(0.12) 0 0.48 0.78 0.45 0.84 0.43
Caucasian Dominant model 1437 / 1341 1.33 0.87–2.05(0.18) 83.6 ≤0.001 1.04 0.29 0.62 0.55
Recessive model 1437 / 1341 0.84 0.49–1.44(0.52) 62.8 ≤0.001 −1.73 0.08 −0.69 0.51
Allelic model 1437 / 1341 1.08 0.81–1.45(0.59) 82.1 ≤0.001 −0.21 0.83 0.2 0.82
ff vs. FF 1437 / 1341 1.28 0.56–2.94(0.55) 81 ≤0.001 −0.25 0.80 −0.68 0.52
Ff vs. FF 1437 / 1341 1.33 0.90–1.98(0.15) 75.5 ≤0.001 1.25 0.21 0.56 0.59
TaqI (rs731236)
Overall Dominant model 4188 / 3955 1.05 0.93–1.19(0.41) 14 0.27 0.45 0.65 0.40 0.69
Recessive model 4188 / 3955 1.07 0.88–1.30(0.48) 31.5 0.08 0.05 0.96 −0.23 0.83
Allelic model 4188 / 3955 1.06 0.97–1.16(0.23) 2.6 0.42 −0.18 0.85 −0.21 0. 83
tt vs. TT 4188 / 3955 1.27 1.01–1.59(0.04) 0 0.68 0.05 0.96 −0.06 0.95
Tt vs. TT 4188 / 3955 1.04 0.91–1.18(0.59) 34.5 0.05 0.45 0.65 0.33 0.74
East-Asian Dominant model 2118/ 2241 0.94 0.76–1.16(0.55) 0 0.56 0.19 0.85 −0.19 0.85
Recessive model 2118/ 2241 0.97 0.50–1.88(0.92) 0 0.68 −0.49 0.62 −1.45 0.24
Allelic model 2118/ 2241 0.95 0.79–1.15(0.60) 0 0.51 −1.69 0.09 −1.27 0.27
tt vs. TT 2118/ 2241 1.02 0.51–2.02(0.96) 0 0.50 −0.98 0.32 −1.70 0.18
Tt vs. TT 2118/ 2241 0.94 0.76–1.16(0.26) 0 0.67 0.56 0.57 0.37 0.73
Caucasian Dominant model 2070 / 1714 1.12 0.96–1.29(0.15) 20.3 0.22 0.09 0.92 −0.03 0.97
Recessive model 2070 / 1714 1.08 0.88–1.33(0.44) 44.1 0.03 1.16 0.24 0.92 0.38
Allelic model 2070 / 1714 1.09 0.98–1.21(0.09) 4.5 0.40 1.34 0.18 1.58 0.15
tt vs. TT 2070 / 1714 1.30 1.02–1.65(0.03) 0 0.62 1.52 0.12 2.35 0.04
Tt vs. TT 2070 / 1714 1.10 0.93–1.29(0.56) 45.7 0.02 −0.80 0.42 −0.41 0.69
BsmI (rs1544410)
Overall Dominant model 3065/2915 0.97 0.84–1.12(0.69) 12 0.31 0.41 0.68 - 0.04 0.96
Recessive model 3065/2915 0.98 0.86–1.12(0.74) 38.7 0.06 0.27 0.78 0.46 0.65
Allelic model 3065/2915 0.99 0.91–1.08(0.82) 42.5 0.03 0.55 0.58 0.74 0.47
bb vs. BB 3065/2915 0.95 0.79–1.14(0.56) 22.2 0.21 0.27 0.78 0.10 0.92
Bb vs. BB 3065/2915 0.97 0.83–1.14(0.74) 0.8 0.44 0 1 0.38 0.71
East-Asian Dominant model 1783 / 1686 0.86 0.71–1.05(0.41) 0 0.76 0.52 0.60 −0.47 0.72
Recessive model 1783 / 1686 0.88 0.73–1.05(0.16) 0 0.59 −1.00 0.31 – –
Allelic model 1783 / 1686 0.89 0.79–1.01(0.06) 0 0.58 0.52 0.60 −0.04 0.97
bb vs. BB 1783 / 1686 0.78 0.60–1.00(0.05) 0 0.88 −1.00 0.31 – –
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the VDR protein and BsmI SNP can modify the VDR
protein expression [74, 75]. Additionally, ApaI and TaqI
SNPs have been shown to have potential to modify the
mRNA transcription of VDR gene and can modulate the
stability of VDR mRNA [21]. FokI SNP has been shown
to have potential to modulate the function of transcrip-
tion factors [76, 77].
A recent meta-analysis by González-Castro in 2019
[78], including 23 studies (a total of 1536 cases/1767
controls for ApaI polymorphism, 1571 cases/ 1455 con-
trols for BsmI polymorphism, 2145 cases/2280 controls
for FokI polymorphism, and 2160 cases/2307 controls
for TaqI polymorphism), indicated that BsmI poly-
morphism had a protective association with nephro-
lithiasis in the allelic and homozygous models.
Moreover, both TaqI polymorphism and FokI poly-
morphism were associated with a decreased risk of
nephrolithiasis in the heterozygous model. However, no
association of ApaI polymorphism was detected with
nephrolithiasis. However, our most recent update meta-
analysis in 2020, by including 33 studies (a total of 2950
cases/3065 controls for ApaI polymorphism, 3065 cases/
2915 controls for BsmI polymorphism, 3114 cases/3174
controls for FokI polymorphism, and 4188 cases/3955
controls for TaqI polymorphism), indicated that none of
the VDR gene polymorphisms mentioned above were as-
sociated significantly with nephrolithiasis risk in the
overall analysis except ApaI SNP. However, our sub-
group analysis according to population stratification re-
vealed that ApaI gene polymorphism increased risk of
urolithiasis in East-Asian patients by the recessive, allelic
and homozygous model and TaqI gene SNP in Cauca-
sians population through the heterozygous model. On
the other hand, a meta-analysis in 2014 with respect to
the study of the associations between VDR gene SNPs
and urolithiasis risk included 20 studies in the analysis
[53]. They found that the TaqI polymorphism was asso-
ciated with an increased risk of urolithiasis, whereas the
ApaI, BsmI, and FokI polymorphisms did not show any
significant association. Moreover, stratifying for ethni-
city, a slightly increased risk was found among Asians as
compared with Whites for TaqI SNP. On the other
hand, our meta-analysis on 33 studies did not result in
any strong significant association between all four SNPs
and urolithiasis risk in the pooled overall comparison.
However, subgroup analysis demonstrated a significant
Table 3 Main results of pooled ORs in meta-analysis of VDR gene polymorphisms (Continued)
Subgroup Sample size Test of association Test of
heterogeneity
Test of publication bias
(Begg’s test)
Test of publication bias
(Egger’s test)
Genetic model Case/Control OR 95%CI (p-value) I2 (%) P Z P T P
Bb vs. BB 1783 / 1686 0.91 0.73–1.12(0.36) 0 0.81 −0.52 0.60 0.87 0.54
Caucasian Dominant model 1282/ 1229 1.11 0.90–1.36(0.34) 18.6 0.26 0 1 0.22 0.83
Recessive model 1282/ 1229 1.11 0.91–1.35(0.30) 45.3 0.05 0.49 0.62 0.81 0.45
Allelic model 1282/ 1229 1.10 0.97–1.24(0.12) 43.2 0.06 0.83 0.40 0.92 0.38
bb vs. BB 1282/ 1229 1.16 0.89–1.50(0.26) 21.5 0.24 0.99 0.32 0.47 0.65
Bb vs. BB 1282/ 1229 1.06 0.84–1.32(0.63) 20.7 0.24 - 0. 21 0.83 - 0.09 0.93
ApaI (rs7975232)
Overall Dominant model 2950 / 3065 1.08 0.93–1.25(0.30) 48.6 0.01 - 0.35 0.72 - 0.54 0.60
Recessive model 2950 / 3065 1.14 1.01–1.29(0.03) 3.5 0.41 - 0.38 0.70 - 0.02 0.98
Allelic model 2950 / 3065 1.09 1.00–1.18(0.05) 31 0.11 - 0.64 0.52 0..42 0.67
aa vs. AA 2950 / 3065 1.21 1.00–1.47(0.05) 27.5 0.14 - 1.15 0.25 - 0.85 0.41
Aa vs. AA 2950 / 3065 1.10 0.94–1.28(0.29) 41.1 0.04 - 0.94 0.34 - 0.39 0.70
East-Asian Dominant model 2186/ 2336 1.15 0.96–1.38(0.12) 38.8 0.13 0.19 0.85 0.21 0.84
Recessive model 2186/ 2336 1.20 1.05–1.37(≤0.001) 32 0.18 1.69 0.09 1.37 0.24
Allelic model 2186/ 2336 1.15 1.05–1.26(≤0.001) 49.1 0.06 0.19 0.85 - 0.09 0.93
aa vs. AA 2186/ 2336 1.40 1.12–1.75(≤0.001) 36.1 0.15 - 0.19 0.85 0.45 0.67
Aa vs. AA 2186/ 2336 1.10 0.90–1.33(0.35) 40.7 0.12 0.56 0.57 0.54 0.62
Caucasian Dominant model 764 / 729 0.96 0.75–1.22(0.73) 55.4 0.02 - 0.83 0.40 - 1.14 0.29
Recessive model 764 / 729 0.86 0.64–1.17(0.34) 0 0.94 0.49 0.62 - 0.25 0.81
Allelic model 764 / 729 0.94 0.80–1.09(0.40) 0 0.75 0.42 0.67 0.60 0.56
aa vs. AA 764 / 729 0.83 0.58–1.20(0.32) 0 0.68 - 0.99 0.32 - 1.32 0.23
Aa vs. AA 764 / 729 1.10 0.85–1.42(0.45) 47.9 0.05 - 1.25 0.21 - 1.40 0.20
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increased risk of urolithiasis in East-Asian and Cauca-
sians populations in association with ApaI and TaqI
genes polymorphism. In the current meta-analysis, thir-
teen more studies were added in comparison to the pre-
vious study, and did not support the previous finding in
the overall analysis.
The subgroup analyses were conducted based on the
ethnicity to identify the potential impression of the gen-
etic background on the association of VDR gene poly-
morphisms and urolithiasis. Our analysis resulted in
identification of ApaI and TaqI polymorphism associ-
ation with increased risk of urolithiasis in East-Asian
and Caucasians populations. However, the previous
meta-analysis identified the same association in only
Asians [53]. These discrepancies may stem from diver-
sities in the genetic backgrounds. Furthermore, given
that solar UV radiation is involved in the process of vita-
min D generation [79], the significant association of
VDR gene TaqI SNP in Asians might be attributed to
the partially higher amount of exposure to UVR [80].
Moreover, it has been implied that level of UV exposure
may impress that the associations between VDR gene
polymorphisms and disorders. In patients with non-
Hodgkin lymphoma, it was reported that patients with
CC genotype for TaqI SNP who experienced sun expos-
ure less than 7 h per week exhibited higher risk of the
disease in comparison to patients with TT genotype with
the similar duration of sun exposure [81]. In addition,
reports showed that the TaqI T allele was more com-
mon in prostate cancer patients in a southern European
population compared with the controls [82]. Plus, in a
British population, the association of FokI polymorphism
was observed to be limited to cases with a high exposed
to UV [83]. Other than that, gender has been known as
also a major risk factor for urolithiasis risk. It was shown
that the FokI polymorphism had significant differences
in females but not males, implying to the role of gender
on the function of VDR [44]. Nonetheless, lack of suffi-
cient data hindered the subgroup analysis based on gen-
der in the current meta-analysis, which need to be
addressed in the further studies.
Data from GWASs as well as association studies in dif-
ferent ethnic groups have revealed that VDR gene poly-
morphisms play a role in altering the risk of urolithiasis
Fig. 3 Begg’s funnel plot for publication bias test. a; Dominant Model FokI, b; Dominant Model TaqI, c; Dominant Model BsmI, d; Dominant
Model ApaI. Each point represents a separate study for the indicated association
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Fig. 4 Sensitivity analysis in present meta-analysis investigates the single nucleotide polymorphisms of Vitamin D Receptor contribute to risk for
urolithiasis susceptibility (a, FokI; b, TaqI; c, BsmI; d, ApaI)
Table 4 Meta-regression analyses of potential source of heterogeneity
Heterogeneity Factor Coefficient SE T-test P-value 95% CI
UL LL
FokI
Dominant Publication Year −0.031 0.03 −0.87 0.39 −0.108 0.045
Genotyping Method −0.032 0.16 −0.20 0.84 −0.370 0.306
TaqI
Dominant Publication Year −0.011 0.01 −0.86 0.40 −0.037 0.015
Genotyping Method 0.018 0.04 0.42 0.67 −0.073 0.109
BsmI
Dominant Publication Year −0.025 0.013 −1.93 0.07 −0.054 0.002
Genotyping Method −0.056 0.58 −0.97 0.34 −0.181 0.068
ApaI
Dominant Publication Year 0.012 0.018 0.68 0.50 −0.026 0.051
Genotyping Method 0.050 0.051 0.99 0.34 −0.059 0.160
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development. Although our analysis did not endorse the
association of VDR gene BsmI, ApaI, FokI, and TaqI
SNPs with susceptibility to urolithiasis, the gene can be
of beneficial applications in populations with significant
associations. Generally, the concept of personalized
medicine has been widely accepted, implying to the
consideration of genetic makeup of each patient in ap-
proaching with optimized medication. As a consequence,
clarification of VDR gene polymorphisms contribution
to the urolithiasis predisposition could be advantageous
in clinics with respect to better diagnosis of subjects at
risk as well as treatment with maximum efficacy.
Despite we tried to perform the possibly well-suited
analysis of the available data, a number of caveats and
confining factors are related to this meta-analysis. First,
our literature search was limited to only English-written
papers, raising the chance of excluding of potentially
worthwhile findings. Second, we could not analyze the
role of age, gender, lifestyle, and other genetic variations,
on the adjusted association of VDR gene SNPs and
urolithiasis risk. Hence, additional works with respect to
the gene–gene and gene–environment interactions is
needed to approach with a more comprehensive estima-
tion. Third, we noticed a significant heterogeneity
among the studies for various comparisons, which may
impress the perception of findings. Although we con-
ducted subgroup analysis and weighted meta-regression
in order to attenuate its effects. Finally, there were a
number of VDR gene SNPs in the context of urolithia-
sis risk that could not be included in the meta-analysis
due to lack of sufficient amount of data. Hence, it could
barely implied that VDR gene could not convey a gen-
etic risk factor for urolithiasis, merely regarding our
findings.
Conclusion
In conclusion, the results of pooled analysis did not
demonstrate any statistically significant association
between all four SNPs and susceptibility to urolithia-
sis. However, subgroup analysis showed that the
Fig. 5 Meta-regression plots of the association between VDR gene polymorphisms and risk of urolithiasis (Dominant model) based on; a:
Publication year (FokI), b: Publication year (TaqI), c: Genotyping method (BsmI), d: Genotyping method (ApaI)
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Recessive, allelic, and aa vs. AA model of ApaI and
Tt vs. TT comparison of the TaqI gene polymorph-
ism increased risk of urolithiasis in East-Asian and
Caucasians population, respectively. Further genes
should be evaluated to disclose the genetic mecha-
nisms contributing to urolithiasis development. More-
over, the role of life style, age, and gender needs be
considered in the stratification analyses for VDR gene
SNPs and urolithiasis predisposition.
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